Renaissance Technologies LLC Invests $421,000 in Invivyd, Inc. (NASDAQ:IVVD)

Renaissance Technologies LLC purchased a new stake in shares of Invivyd, Inc. (NASDAQ:IVVD) during the second quarter, Holdings Channel.com reports. The fund purchased 382,818 shares of the company’s stock, valued at approximately $421,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Chase Investment Counsel Corp purchased a new stake in Invivyd during the first quarter worth about $271,000. SG Americas Securities LLC purchased a new stake in shares of Invivyd during the 1st quarter worth approximately $56,000. Vanguard Group Inc. raised its holdings in shares of Invivyd by 3.9% in the 1st quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock worth $11,594,000 after purchasing an additional 97,496 shares during the period. Acadian Asset Management LLC purchased a new position in Invivyd in the first quarter valued at approximately $905,000. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Invivyd by 21.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company’s stock valued at $1,933,000 after purchasing an additional 77,603 shares during the period. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Invivyd in a report on Tuesday, September 3rd.

Invivyd Stock Performance

Shares of IVVD stock opened at $0.90 on Friday. The company has a market capitalization of $107.90 million, a PE ratio of -0.48 and a beta of 0.63. Invivyd, Inc. has a 52-week low of $0.81 and a 52-week high of $5.20. The business’s fifty day moving average is $1.00 and its 200 day moving average is $1.68.

Invivyd (NASDAQ:IVVD) last released its earnings results on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.03). The company had revenue of $2.26 million during the quarter, compared to analyst estimates of $4.91 million. On average, sell-side analysts forecast that Invivyd, Inc. will post -0.6 EPS for the current fiscal year.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.